CN104707126A - 一种治疗肺炎链球菌感染性肺炎的药物及制备方法 - Google Patents
一种治疗肺炎链球菌感染性肺炎的药物及制备方法 Download PDFInfo
- Publication number
- CN104707126A CN104707126A CN201510167902.9A CN201510167902A CN104707126A CN 104707126 A CN104707126 A CN 104707126A CN 201510167902 A CN201510167902 A CN 201510167902A CN 104707126 A CN104707126 A CN 104707126A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- herba
- rhizoma
- semen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 92
- 241000193998 Streptococcus pneumoniae Species 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 23
- 201000005010 Streptococcus pneumonia Diseases 0.000 title abstract 3
- 239000000463 material Substances 0.000 claims abstract description 20
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- 210000000582 semen Anatomy 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 28
- 239000008187 granular material Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 24
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 24
- 239000009636 Huang Qi Substances 0.000 claims description 23
- 239000008517 radix Trichosanthis Substances 0.000 claims description 22
- 241000756943 Codonopsis Species 0.000 claims description 21
- 244000025254 Cannabis sativa Species 0.000 claims description 20
- 244000183685 Citrus aurantium Species 0.000 claims description 19
- 240000008669 Hedera helix Species 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 239000007921 spray Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 13
- 238000010992 reflux Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000013521 mastic Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000005325 percolation Methods 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 206010013786 Dry skin Diseases 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 230000000274 adsorptive effect Effects 0.000 claims description 3
- 125000003158 alcohol group Chemical group 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229960004793 sucrose Drugs 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 abstract description 65
- 230000001737 promoting effect Effects 0.000 abstract description 19
- 238000004519 manufacturing process Methods 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 17
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 4
- 244000273928 Zingiber officinale Species 0.000 abstract description 4
- 235000008397 ginger Nutrition 0.000 abstract description 4
- 230000001502 supplementing effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 241001494508 Arundo donax Species 0.000 abstract description 2
- 241000220154 Parnassia Species 0.000 abstract description 2
- 240000005523 Peganum harmala Species 0.000 abstract description 2
- 235000005126 Peganum harmala Nutrition 0.000 abstract description 2
- 241000608133 Platanthera Species 0.000 abstract description 2
- 244000028344 Primula vulgaris Species 0.000 abstract description 2
- 241001412627 Adenophora liliifolia Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000202903 Bergenia purpurascens Species 0.000 abstract 1
- 241001061906 Caragana Species 0.000 abstract 1
- 241000518307 Cassytha Species 0.000 abstract 1
- 241000721183 Circaea Species 0.000 abstract 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 abstract 1
- 240000003791 Citrus myrtifolia Species 0.000 abstract 1
- 235000016646 Citrus taiwanica Nutrition 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 244000074881 Conyza canadensis Species 0.000 abstract 1
- 235000004385 Conyza canadensis Nutrition 0.000 abstract 1
- 244000182067 Fraxinus ornus Species 0.000 abstract 1
- 235000002917 Fraxinus ornus Nutrition 0.000 abstract 1
- 241000605372 Fritillaria Species 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241000197861 Leucas Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 240000008467 Oryza sativa Japonica Group Species 0.000 abstract 1
- 241001300112 Peucedanum medicum Species 0.000 abstract 1
- 235000014676 Phragmites communis Nutrition 0.000 abstract 1
- 235000006751 Platycodon Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 abstract 1
- 235000016311 Primula vulgaris Nutrition 0.000 abstract 1
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 235000014443 Pyrus communis Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 235000001486 Salvia viridis Nutrition 0.000 abstract 1
- 244000258070 Salvia viridis Species 0.000 abstract 1
- 241001180876 Saposhnikovia Species 0.000 abstract 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 abstract 1
- 240000006023 Trichosanthes kirilowii Species 0.000 abstract 1
- 241000046198 Triteleia hyacinthina Species 0.000 abstract 1
- 241001448528 Tupistra Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 210000000994 inner shell membrane Anatomy 0.000 abstract 1
- 229930189914 platycodon Natural products 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 51
- 239000008280 blood Substances 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 34
- 208000002193 Pain Diseases 0.000 description 28
- 230000036407 pain Effects 0.000 description 28
- 235000009508 confectionery Nutrition 0.000 description 25
- 238000011282 treatment Methods 0.000 description 25
- 230000001717 pathogenic effect Effects 0.000 description 24
- 206010062717 Increased upper airway secretion Diseases 0.000 description 19
- 208000026435 phlegm Diseases 0.000 description 19
- 210000002784 stomach Anatomy 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 17
- 210000001124 body fluid Anatomy 0.000 description 15
- 239000010839 body fluid Substances 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 206010047700 Vomiting Diseases 0.000 description 14
- 206010012735 Diarrhoea Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 13
- 239000003172 expectorant agent Substances 0.000 description 13
- 230000003419 expectorant effect Effects 0.000 description 13
- 208000033809 Suppuration Diseases 0.000 description 12
- 210000000038 chest Anatomy 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 11
- 230000008673 vomiting Effects 0.000 description 11
- 206010007247 Carbuncle Diseases 0.000 description 9
- 229930182555 Penicillin Natural products 0.000 description 9
- 206010003549 asthenia Diseases 0.000 description 9
- 210000003128 head Anatomy 0.000 description 9
- 229940049954 penicillin Drugs 0.000 description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 8
- 206010037660 Pyrexia Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 231100000869 headache Toxicity 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 210000001835 viscera Anatomy 0.000 description 8
- 206010000087 Abdominal pain upper Diseases 0.000 description 7
- 208000000059 Dyspnea Diseases 0.000 description 7
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- 206010068319 Oropharyngeal pain Diseases 0.000 description 7
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 7
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 7
- 208000019790 abdominal distention Diseases 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 208000001848 dysentery Diseases 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 208000022218 streptococcal pneumonia Diseases 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 201000007100 Pharyngitis Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 208000001431 Psychomotor Agitation Diseases 0.000 description 6
- 206010038743 Restlessness Diseases 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000002398 materia medica Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 5
- 208000031971 Yin Deficiency Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 210000003026 hypopharynx Anatomy 0.000 description 5
- 201000003453 lung abscess Diseases 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 230000003448 neutrophilic effect Effects 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 208000037656 Respiratory Sounds Diseases 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 206010043458 Thirst Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000013116 chronic cough Diseases 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 231100000019 skin ulcer Toxicity 0.000 description 4
- 230000035943 smell Effects 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010033425 Pain in extremity Diseases 0.000 description 3
- 201000005702 Pertussis Diseases 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 229960004261 cefotaxime Drugs 0.000 description 3
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 3
- 229960004755 ceftriaxone Drugs 0.000 description 3
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 3
- 238000007596 consolidation process Methods 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 208000017574 dry cough Diseases 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 206010029410 night sweats Diseases 0.000 description 3
- 230000036565 night sweats Effects 0.000 description 3
- 238000009527 percussion Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004206 stomach function Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 231100000611 venom Toxicity 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- 206010012218 Delirium Diseases 0.000 description 2
- 206010013952 Dysphonia Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000010473 Hoarseness Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 208000004356 Hysteria Diseases 0.000 description 2
- 208000032923 Lobar pneumonia Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 206010044302 Tracheitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical class S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 208000012839 conversion disease Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 206010037833 rales Diseases 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 230000008359 toxicosis Effects 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000007743 Acute Abdomen Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 241001092371 Bergenia Species 0.000 description 1
- 240000001889 Brahea edulis Species 0.000 description 1
- 235000015917 Brahea edulis Nutrition 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 241000131758 Caryopteris Species 0.000 description 1
- 241000054262 Cassytha capillaris Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241001517488 Clavus Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010062317 Condyloma latum Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000219764 Dolichos Species 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061298 Mucosal haemorrhage Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241000219929 Onagraceae Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- 241000290143 Pyrus x bretschneideri Species 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241001621801 Rohdea chinensis Species 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000003861 Umbilicariaceae Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 241000159213 Zygophyllaceae Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000024753 bloody sputum Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229940031960 pneumococcal polysaccharide vaccine Drugs 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000010707 pulmonary consolidation Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002396 uvula Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗肺炎链球菌感染性肺炎的药物及制备方法,其中,药物包括以下原料药材:沙参、梨皮、天花粉、葛根、贝母、玉竹、竹根七、石耳、芦竹根、杉叶藻、猪獠参、生黄芪、党参、凤凰衣、鸡肫草、甘草、霜桑叶、桔梗、骆驼蓬、光头前胡、六月寒、水珠草、生地黄、粳米、无爷藤、柠条、蜂窝草、樱草根、岩白菜、淡豆豉、白扁豆、防风、生姜和玳玳花。本发明的有益效果是:本发明具有清热润肺的功效,兼以养阴生津、益气补肺、除风通络,主治燥邪伤肺型肺炎链球菌感染性肺炎;且制作工艺简便,毒副作用小且给药方便,药剂易于制造,成本低廉的新药,能直达病灶,治愈时间短,治愈后不易复发。
Description
技术领域
本发明涉及药学技术领域,特别涉及一种治疗肺炎链球菌感染性肺炎的药物及制备方法。
背景技术
肺炎链球菌肺炎是由肺炎链球菌或称肺炎球菌所引起的肺炎,约占社区获得性肺炎的半数。通常起病急骤,以高热、寒战、咳嗽、血痰及胸痛为特征。X线胸片呈肺段或肺叶急性炎性实变。
一般四季可见,但以冬季最多。本病最常见于年龄太小或太老的病人,咽部细菌检查表明,5%~25%的健康人为肺炎球菌的带菌者,冬季儿童及幼儿的父母检出率最高。根据荚膜多糖抗原分类,肺炎球菌有80种以上的血清型。
病因
肺炎链球菌为革兰氏染色阳性球菌,多呈双排列或短链排列。除引起肺炎外,少数可发生菌血症或感染性休克,老年人及婴幼儿的病情尤为严重。
肺炎链球菌肺炎以冬季与初春多见,患者常为原先健康的青壮年或5岁以下小儿和60岁以上老人。近年来由于抗菌药物的广泛应用,临床上症状轻或不典型病较为多见。小儿可通过疫苗进行预防。目前可接种的肺炎球菌疫苗有7价肺炎球菌结合疫苗和23价肺炎球菌多糖疫苗,2岁以下婴儿只能接种7价肺炎球菌结合疫苗。
发病机制
肺炎球菌一般通过吸入,经上呼吸道到达肺部。它们停留在细支气管内增殖并引起炎症过程,开始在肺泡腔内产生大量蛋白质的液体,这种液体起着病菌培养介质的作用,并可帮助病菌向邻近肺泡扩散,典型的结果是导致大叶性肺炎。
大叶性肺炎的最初阶段是充血,特点是大量浆液性渗出物,血管扩张及细菌迅速增殖。下一阶段叫做"红色肝样变",即实变的肺脏呈肝样外观:气腔充满多形核细胞,血管充血及红细胞外渗,因此肉眼检查呈淡红色.接着是"灰色肝样变"期,该期的纤维蛋白集聚与处于不同分解阶段的白细胞和红细胞有关,肺泡腔充满炎症渗出物。最后阶段是以渗出物吸收为特征的消散期。
临床表现
症状
发病前常有受凉、淋雨、疲劳、酗酒、病毒感染史,多有上呼吸道感染的前驱症状,起病多急骤,高热、寒战,全身肌肉酸痛,体温通常在数小时内升至39~40℃,高峰在下午或傍晚,或呈稽留热,脉速随之增速。可有患侧胸部疼痛,放射到肩部或腹部,咳嗽或深呼吸时加剧,痰少,可带血或铁锈色,胃纳锐减,偶有恶心、呕吐、腹痛或腹泻,易被误诊为急腹症。
体征
患者呈急性热病容,面颊绯红,鼻翼煽动,皮肤灼热、干燥,口角及鼻周有单纯胞疹;病变广泛时可出现紫绀。有败血症者,可出现皮肤、粘膜出血点,巩膜黄染。早期肺部体征无明显异常,仅有胸廓呼吸运动幅度减小,叩诊稍浊,听诊可有呼吸音降低及胸膜摩擦音。肺实变时叩诊浊音、触觉语颤增强并可闻及支气管呼吸音。消退期可闻及湿罗音。心率增快,有时心律不齐。重症患者有肠胀气,上腹部压痛多与膈胸膜有关。重症感染时可伴休克、急性呼吸窘迫综合征及神经精神症状,表现为神志模糊、烦躁、呼吸困难、嗜睡、谵妄、昏迷。累及脑膜时有颈抵抗及出现病理反射。
肺炎链球菌肺炎的自然病程大致1~2周。发病5~10天,体温可自行骤降或逐渐消退;使用有效抗菌药物后可使体温在1~3天内恢复正常。患者的其它症状与体征亦随之消失。
并发症
肺炎链球菌肺炎的并发症近年已很少见。严重败血症或毒血症患者易发生感染性休克,尤其是老年人,表现为血压降低、四肢厥冷、多汗、发绀、心动过速、心律失常等,而高热、胸痛、咳嗽等症状并不突出。其它并发症有胸膜炎、脓胸、心包炎、脑膜炎和关节炎等。
治疗
对青霉素敏感的肺炎球菌株,青霉素G是首选药物。非重症患者可口服青霉素G或V250~500mg,每6小时1次;对无并发症的肺炎球菌肺炎推荐给予水剂青霉素G50~200万u静脉注射,每4~6小时1次。
约25%的肺炎球菌对青霉素耐药。在美国,临床上分离的菌株中,青霉素相对或高度耐药率为15%~30%,而在世界其他地区,特别是西班牙,日本,以色列,南非和西欧,耐药率更高。许多青霉素耐药菌株对其他抗生素同样耐药,含1μg苯唑青霉素的平皿适用于检测耐药菌株,抑菌圈≤19mm的分离物应再采用肉汤稀释剂检测。对高度耐药菌株的治疗,应根据体外药敏试验大剂量青霉素,头孢噻肟或头孢曲松对大多数耐药菌株有效。新一代喹诺酮类药物(左旋氧氟沙星,司帕沙星,格帕沙星和托法沙星)是青霉素耐药菌株的常选用的药物,也可为青霉素敏感菌株治疗的可供替换的药物。万古霉素作为唯一一种具有持久活性的药物,对所有肺炎球菌均有抗菌活性,可作为在大多数情况下伴有高耐青霉素发生率的重症患者的首选药物。
其他有效的药物包括头孢霉素类,红霉素和克林霉素。四环素抗肺炎球菌效果的可靠性较差,病情严重的病人不应使用。口服用药包括红霉素或林可霉素300mg,每6小时1次。胃肠道外用药包括头孢噻肟1~2g静脉注射,每6小时1次;头孢曲松1~2g静脉注射,每12小时1次;头孢唑啉500mg静脉注射,每8小时1次,红霉素0.5~1g静脉注射,每6小时1次;或克林霉素300~600mg静脉注射,每6~8小时1次.除头孢噻肟和头孢曲松外,大多数第三代头孢霉素对肺炎球菌相对无抗菌活性。
但是,西医治疗肺炎链球菌肺炎,疗程较长,长期大量应用抗生素、祛痰剂易产生耐药性,临床疗效不甚理想,病情易反复发作,严重影响患者的生活质量等。
中医分为以下几种类型:痰热壅肺型、热闭心神型、温邪犯肺型和燥邪伤肺型。其中燥邪伤肺型,证见唇、舌、鼻均干,干咳少痰,痰粘难以咯出,咽喉干痛,口渴,舌红,脉数。
中医药治疗肺炎链球菌肺炎,具备独特的优势与特点:利用传统中医理论,在整体观的基础上,通过调节气血循环,增强机体免疫力,进行辨证论治,据不同的病证多靶点治疗,增强呼吸肌的呼吸功能,促进排痰止咳、平喘,保持呼吸道通畅,药效直达病灶,安全有效,疗程较短,且不易产生耐药性、成本价较低、给药方便,病人易于接受,可明显提高治愈率,降低并发症、降低复发率,显著提高患者的生活质量等。
发明内容
本发明要解决的技术问题在于提供一种治疗肺炎链球菌感染性肺炎的药物及制备方法,本发明具有清热润肺的功效,兼以养阴生津、益气补肺、除风通络,主治燥邪伤肺型肺炎链球菌感染性肺炎。本发明利用传统中医理论,配方简单、制作工艺简便,毒副作用小且给药方便,药剂易于制造,成本低廉的新药。本发明为药物制剂,但精选气味平和的中药,使中药制剂的气味并不浓烈。本发明采用不同药性的中药材,进行了科学配伍,能达到理想的治疗效果,且安全,毒副作用小,制备简单,能直达病灶,治愈时间短,治愈后不易复发。
为了实现上述发明目的,本发明提供了一种治疗肺炎链球菌感染性肺炎的药物,包括以下原料药材:沙参、梨皮、天花粉、葛根、贝母、玉竹、竹根七、石耳、芦竹根、杉叶藻、猪獠参、生黄芪、党参、凤凰衣、鸡肫草、甘草、霜桑叶、桔梗、骆驼蓬、光头前胡、六月寒、水珠草、生地黄、粳米、无爷藤、柠条、蜂窝草、樱草根、岩白菜、淡豆豉、白扁豆、防风、生姜和玳玳花。
所述药物中各原料药材的重量份数比为:沙参22-32份、梨皮12-21份、天花粉5-9份、葛根20-30份、贝母16-25份、玉竹17-27份、竹根七9-15份、石耳10-16份、芦竹根13-20份、杉叶藻12-17份、猪獠参10-15份、生黄芪26-39份、党参16-29份、凤凰衣6-11份、鸡肫草12-16份、甘草10-18份、霜桑叶8-16份、桔梗14-21份、骆驼蓬12-16份、光头前胡7-14份、六月寒5-11份、水珠草12-17份、生地黄28-38份、粳米9-17份、无爷藤10-19份、柠条6-12份、蜂窝草8-14份、樱草根10-15份、岩白菜14-20份、淡豆豉13-19份、白扁豆15-25份、防风11-16份、生姜11-19份和玳玳花13-19份。
所述药物中各原料药材的重量份数比为:沙参24-30份、梨皮15-19份、天花粉6-8份、葛根22-28份、贝母18-23份、玉竹19-25份、竹根七10-14份、石耳11-15份、芦竹根15-19份、杉叶藻13-16份、猪獠参11-14份、生黄芪27-35份、党参19-27份、凤凰衣7-10份、鸡肫草13-15份、甘草11-17份、霜桑叶9-15份、桔梗15-20份、骆驼蓬13-15份、光头前胡8-12份、六月寒6-10份、水珠草13-15份、生地黄29-36份、粳米10-15份、无爷藤11-17份、柠条7-11份、蜂窝草9-13份、樱草根11-14份、岩白菜15-19份、淡豆豉14-18份、白扁豆17-23份、防风12-15份、生姜12-17份和玳玳花14-16份。
所述药物中各原料药材的重量份数比为:沙参24份、梨皮19份、天花粉7份、葛根22份、贝母23份、玉竹22份、竹根七10份、石耳15份、芦竹根18份、杉叶藻15份、猪獠参11份、生黄芪31份、党参19份、凤凰衣10份、鸡肫草15份、甘草17份、霜桑叶9份、桔梗20份、骆驼蓬13份、光头前胡12份、六月寒6份、水珠草13份、生地黄36份、粳米15份、无爷藤13份、柠条9份、蜂窝草12份、樱草根11份、岩白菜18份、淡豆豉18份、白扁豆21份、防风15份、生姜12份和玳玳花16份。
所述药物中各原料药材的重量份数比为:沙参27份、梨皮17份、天花粉6份、葛根28份、贝母18份、玉竹25份、竹根七12份、石耳13份、芦竹根15份、杉叶藻16份、猪獠参13份、生黄芪35份、党参27份、凤凰衣9份、鸡肫草13份、甘草16份、霜桑叶11份、桔梗15份、骆驼蓬14份、光头前胡11份、六月寒10份、水珠草14份、生地黄29份、粳米11份、无爷藤11份、柠条11份、蜂窝草13份、樱草根14份、岩白菜15份、淡豆豉16份、白扁豆17份、防风13份、生姜17份和玳玳花15份。
所述药物中各原料药材的重量份数比为:沙参30份、梨皮15份、天花粉8份、葛根26份、贝母21份、玉竹19份、竹根七14份、石耳11份、芦竹根19份、杉叶藻13份、猪獠参14份、生黄芪27份、党参22份、凤凰衣7份、鸡肫草14份、甘草11份、霜桑叶15份、桔梗18份、骆驼蓬15份、光头前胡8份、六月寒8份、水珠草15份、生地黄33份、粳米10份、无爷藤17份、柠条7份、蜂窝草11份、樱草根12份、岩白菜19份、淡豆豉14份、白扁豆23份、防风12份、生姜16份和玳玳花14份。
所述药物的剂型为喷雾剂时,其制备方法包括以下步骤:
a、按所述比例称取所有原料药材,加相对于获得的混合物质量3-5倍的水浸泡3-10小时,武火煮沸后,改用文火慢煎30-50分钟至药液的剂量为100-300ml,煎煮3次,合并煎煮液过滤,滤液加热得浸膏1,药渣备用;
b、将步骤a的药渣加60-90%乙醇浸泡0.5-1.5小时,提取两次,每次1-2小时,合并提取液,80-160目滤过,取6000-10000转/分钟离心后的上清液,经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩得相对密度为80℃时 1.35的浸膏2;
c、将浸膏1和浸膏2混合,加水稀释即得喷雾剂。
所述药物的剂型为含片剂时,其制备方法包括以下步骤:
第一步,将沙参、梨皮、天花粉、葛根、贝母、玉竹和竹根七所述比例混合,用相对于获得的混合物质量的4~6倍的醇浓度90%~95%的乙醇浸泡,加热回流2~4小时后提取,过滤;将滤渣再次用相对于获得的混合物质量的2~4倍的醇浓度85%~95%的乙醇浸泡,加热回流1~2小时后提取,过滤;合并两次过滤液,减压回收乙醇并浓缩至药液浓度为0.8~1.2g生药/mL,利用体积为5L的大孔吸附树脂柱洗脱两次,先用5倍树脂柱体积的去离子水或蒸馏水洗脱,再用3倍树脂柱体积的醇浓度为90%~95%乙醇洗脱,收集乙醇洗脱液,减压浓缩除去乙醇,干燥并粉碎成粉末;
第二步,将芦竹根、杉叶藻、猪獠参、生黄芪和党参按所述比例混合,加相对于获得的混合物质量的3~5倍的醇浓度85%~95%的乙醇加热回流提取2次,两次提取液合并,用管式离心机离心除杂,将除杂后的提取液于60℃~70℃的条件下减压浓缩至60℃时相对密度为1.20~1.23的膏体,将浓缩后的膏体用喷雾干燥器干燥成粉末;
第三步,将剩余原料药材按所述比例混合,加相对于获得的混合物质量的2~5倍的水浸泡,加热煎煮2~4小时,过滤;将滤渣再次用相对于获得的混合物质量的1~3倍的水浸泡,加热煎煮1~2小时,过滤;合并两次过滤液,减压浓缩除去水分,干燥并粉碎成粉末;
第四步,将第一步、第二步和第三步获得的粉末混合,进一步加入相对于获得的混合物质量0.05~0.1倍的羧甲基淀粉钠、0.05~0.1倍的微晶纤维素,混匀,制粒,干燥后,加入相对于获得的混合物质量0.01~0.05倍的硬脂酸镁,然后用冲压装置将颗粒压制成片,即得含片剂。
所述药物的剂型为颗粒剂时,其制备方法包括以下步骤:
步骤一:将所述原料药材按所述比例混合,加相对于混合物4~8倍的醇浓度为85%~95%的乙醇,加热至沸腾回流3~5小时,过滤,采用渗漉法以每分钟1~2ml的速度缓缓渗漉,收集渗漉液,随后在真空度0.06~0.09Mpa下减压浓缩至50~60℃时相对密度为1.04~1.10的膏体,喷雾干燥,喷雾干燥机的进风温度160~175℃、出风温度80~85℃,随后粉碎成粉末,制成干膏粉;
步骤二:在获得的干膏粉中加入相对于干膏粉质量0.2~0.4倍的蔗糖粉和0.1~0.2倍的糊精,制成颗粒,于40~50℃干燥,获得颗粒剂。
本发明提供的技术方案带来的有益效果是:本发明具有清热润肺的功效,兼以养阴生津、益气补肺、除风通络,主治燥邪伤肺型肺炎链球菌感染性肺炎;配方简单、制作工艺简便,毒副作用小且给药方便,药剂易于制造,成本低廉的新药。本发明为中药制剂,但精选气味平和的中药,使中药制剂的气味并不浓烈。本发明采用不同药性的中药材,进行了科学配伍,能达到理想的治疗效果,且安全,毒副作用小,制备简单,能直达病灶,治愈时间短,治愈后不易复发。
具体实施方式
治疗肺炎链球菌感染性肺炎,本发明以清热润肺为主要治疗原则,选用方剂:沙参、梨皮、天花粉、葛根、贝母、玉竹、竹根七、石耳、芦竹根、杉叶藻、猪獠参、生黄芪、党参、凤凰衣、鸡肫草、甘草、霜桑叶、桔梗、骆驼蓬、光头前胡、六月寒、水珠草、生地黄、粳米、无爷藤、柠条、蜂窝草、樱草根、岩白菜、淡豆豉、白扁豆、防风、生姜和玳玳花。
其中,沙参、梨皮、天花粉、葛根、贝母、玉竹、竹根七、石耳、芦竹根、杉叶藻、猪獠参清热泻火,养阴生津;生黄芪、党参、凤凰衣、鸡肫草益气养阴补肺;甘草、霜桑叶、贝母、桔梗、骆驼蓬、光头前胡、六月寒和水珠草宣降肺气;天花粉、玉竹、生地黄、粳米、无爷藤、柠条益阴养血;甘草、桔梗、蜂窝草、樱草根、岩白菜化痰止咳;淡豆豉、白扁豆、桔梗、防风、生姜、玳玳花除风通络,和胃。
其中,上述原料药材的药理如下:
沙参:别名南沙参、泡参、泡沙参。为桔梗科沙参属植物四叶沙参、杏叶沙参或其同属植物,以根入药。甘,凉。归肺;胃经。清热养阴,润肺止咳。主治气管炎,百日咳,肺热咳嗽,咯痰黄稠。益胃生津。主阴虚久咳;痨嗽痰血;燥咳痰少;虚热喉痹;津伤口渴。
梨皮:为蔷薇科植物白梨、沙梨或秋子梨等的果皮。甘;涩;凉;无毒。归肺;心;肾;大肠经。清心润肺;降火生津,解疮毒。主暑热烦渴;肺燥咳嗽;吐血;痢疾;疥癣;发背;疔疮。
天花粉:甘、微苦,微寒。归肺、胃经。清热生津,消肿排脓。用于热病烦渴,肺热燥咳,内热消渴,疮疡肿毒。
葛根:性凉,味甘、辛,入脾、胃经。可升阳解肌,透疹止泻,除烦止温。治伤寒、温热头痛项强,烦热消渴,泄泻,痢疾,癍疹不透,高血压,心绞痛,耳聋。
贝母:味大苦,性寒;入肺、心、胃、肝经。清热化痰,散结解毒。用治风热咳嗽,肺痈喉痹,瘰疬,疮疡肿毒。
玉竹:味甘,性平;归肺、胃经。养阴润肺,滋胃生津。《药性论》:“主时疾寒热,内补不足,去虚劳客热,头痛不安,加而用之良。”《日华子本草》:“除烦闷,止渴,润心肺,补五劳七伤,虚损,腰脚疼痛,天行热狂。”《本草纲目》:“主风温自汗灼热,及劳疟寒热,脾胃虚乏,男子小便频数,失精,一切虚损。”
竹根七:为百合科植物开口箭的根茎。味甘;微辛;性平。滋阴泻火,活血调经。治劳热咳嗽,风湿痹痛,月经不调,跌打损伤。养阴清肺;活血祛瘀。主虚肺燥;咳嗽咽干;产后虚劳;妇女干痨;跌打损伤;骨折。
石耳:地衣类石耳科石耳属植物石耳,以叶状体入药。甘,平。肺;心;胃经。清热止血,止咳化痰。用于吐血,衄血,崩漏,膀胱炎,肠炎,痢疾,支气管炎。外用治毒蛇咬伤,烧烫伤。
芦竹根:为禾本科植物芦竹的根茎。苦,寒。清热利水。治热病发狂,虚劳骨蒸,淋病,小便不利,风火牙痛。清热泻火;生津除烦;利尿。主热病烦渴;虚劳骨蒸;吐血;热淋;小便不利;风火牙痛。
杉叶藻:杉叶藻科杉叶藻,以全草入药。微甘、苦,凉。镇咳,舒肝,凉血止血,养阴生津,透骨蒸。主治高热烦渴,结核咳嗽,痨热骨蒸,两胁疼痛,肠胃炎等。茎、叶外用治外伤出血。
猪獠参:兰科舌唇兰属植物小舌唇兰,以全草入药。甘,平。养阴润肺,益气生津。用于咳痰带血,咽喉肿痛,病后体弱,神经衰弱,遗精,头晕。
生黄芪:甘,微温;归肺、脾、肝、肾经。补气健脾,益卫实表,升阳举陷,托毒敛疮,利水消肿。《本草备要》:“黄芪,生用固表,无汗能发,有汗能止;炙用补中,益元气,壮脾胃。生血,生肌,排脓内托,疮痈圣药。痘症不起,阳虚无热者宜之。”《本草正义》:“黄芪,补益中土,温养脾胃,凡中气不振,脾土虚弱,清气下陷者最宜。其皮直达人之肤表肌肉,固护卫阳,充实表分,是其专长,所以表虚诸病,最为神剂。”功用固表敛汗,利水消肿,托疮排脓,通调水道。
党参:性平,味甘、微酸;归脾、肺经。补中益气,健脾益肺,养阴生津。用于脾肺虚弱,气短心悸,食少便溏,虚喘咳嗽,内热消渴。
凤凰衣:雉科动物鸡所产卵孵化小鸡后鸡蛋壳的内膜。甘,温。入肺经。补肺止咳。用于慢性气管炎,久咳,盗汗。养阴,清肺.治久咳,咽痛失音,瘰疬结核,溃疡不敛。
鸡肫草:为虎耳科梅花草属植物鸡眼梅花草以全草入药。淡、平。清肺止咳,利水祛湿。用于久咳咯血,疟疾,肾结石,胆石症,白带,跌打损伤;外用治湿热疮毒。
甘草:性味甘,平。入脾、胃、肺经。可益气补中,缓急止痛,润肺止咳,泻火解毒,调和诸药。主倦怠食少,肌瘦面黄,心悸气短,腹痛便溏,四肢挛急疼痛,脏躁,咳嗽气喘,咽喉肿痛,痈疮肿痛,小儿胎毒,及药物、食物中毒。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。《本经》曰:“主五脏六府寒热邪气,坚筋骨,长肌肉,倍力,金疮肿,解毒”。人阴(不)《药性论》曰:“主腹中冷痛,治惊痫,除腹胀满;补益五脏;制诸药毒;养肾气内伤,令痿;主妇人血沥腰痛;虚而多热;加而用之”。可益气补中,缓急止痛,润肺止咳,泻火解毒,调和诸药。主倦怠食少,肌瘦面黄,心悸气短,腹痛便溏,四肢挛急疼痛,脏躁,咳嗽气喘,咽喉肿痛,痈疮肿痛,小儿胎毒,及药物、食物中毒。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
桑叶:味苦、甘、性寒;归肺、肝经。疏散风热,解表清热,养阴生津《本草拾遗》:“主霍乱腹痛吐下,冬月用干者浓煮服之。细锉,大釜中煎取如赤糖,去老风及宿血。”《日华子本草》:“利五脏,通关节,下气,煎服;除风痛出汗,并扑损瘀血,并蒸后罯;蛇虫蜈蚣咬,盐挼敷上。”桑叶能疏散风热,解表清热,养阴生津。
桔梗:味苦,辛,性平。归肺经。具有宣肺、祛痰、利咽、排脓、利五脏、补气血、补五劳、养气的功效。主治咳嗽痰多、咽喉肿痛、肺痈吐脓、胸满胁痛、痢疾腹痛、口舌生疮、目赤肿痛、小便癃闭。用于咳嗽痰多,胸闷不畅,咽痛,音哑,肺痈吐脓,疮疡脓成不溃。《本经》曰:“主胸胁痛如刀刺,腹满,肠鸣幽幽,惊恐悸气”。《日华子本草》曰:“下一切气,止霍乱转筋,心腹胀痛,补五劳,养气,除邪辟温,补虚消痰,破症瘕,养血排脓,补内漏及喉痹”。
骆驼蓬:蒺藜科骆驼蓬属植物骆驼蓬.,以全草及种子入药。酸、甘,平。有毒。宣肺止咳,祛风湿,解毒。
光头前胡:别名岩防风、棕包头、鸡肢前胡、独活、岩棕、官防风。为伞形科植物化中前胡和岩前胡的根及根茎。味辛;苦;性平。归肺;肝经。宣肺祛痰;降气止咳;定惊。主感冒;咳嗽;痰喘;胞闷;风湿痛;小儿惊风。
六月寒:马鞭草科莸属植物三花莸,以全草入药。辛,温。发表散寒,宣肺止咳,活血调经。用于感冒咳嗽,慢性支气管炎,百日咳,通经,产后腹痛;外用治刀伤,烧烫伤,毒蛇咬伤。
水珠草:别名散积血。为柳叶菜科植物水珠草的全草。味辛;苦;性平。宣肺止咳;理气活血;利尿解毒。主外感咳嗽;脘腹胀痛;痛经;月经不调;经闭;泄泻;水肿;淋痛;疮肿;瘭疽;癣痒;湿疣。
生地黄:甘,寒;归心,肝,肾经。清热、生津、润燥、滑肠、破瘀、生新、止痛、调经、凉血、止血活血。《神农本草经》:“味甘,寒。主治折跌,绝筋,伤中,逐血痹,填骨髓,长肌肉。作汤除寒热积聚,除痹。生者尤良。”清热、生津、润燥、滑肠、破瘀、生新、止痛、调经、凉血、止血活血。生地黄性寒,功能为凉血清热、滋阴补肾、生津止渴,常用于治疗骨蒸痨热、咽喉燥痛、痰中带血等症。
粳米:味苦,辛,性平。归肺经。具有宣肺、祛痰、利咽、排脓、利五脏、补气血、补五劳、养气的功效。主治咳嗽痰多、咽喉肿痛、肺痈吐脓、胸满胁痛、痢疾腹痛、口舌生疮、目赤肿痛、小便癃闭。用于咳嗽痰多,胸闷不畅,咽痛,音哑,肺痈吐脓,疮疡脓成不溃。《本经》曰:“主胸胁痛如刀刺,腹满,肠鸣幽幽,惊恐悸气”。《日华子本草》曰:“下一切气,止霍乱转筋,心腹胀痛,补五劳,养气,除邪辟温,补虚消痰,破症瘕,养血排脓,补内漏及喉痹”。
无爷藤:为樟科植物无根藤的全草。甘苦,寒。清热利湿、凉血解毒。治肝热消瘦,肺热咳嗽,黄疸,痢疾,鼻衄,血淋,痈肿,疥疮,烫伤。
柠条:豆科柠条,以根、花、种子入药。全草和花:甘,温。全草和花:滋补养血。甘;温肝;肾经。滋阴补血,活血。主月经不调。此处用全草和花。
蜂窝草:唇形科绣球防风属植物蜂窝草的全草。苦、辛,温。疏风散寒,化痰止咳。感冒,头痛,牙痛,咳嗽,咽喉炎,百日咳,支气管哮喘。
樱草根:为报春花科植物樱草的根及根茎。甘;性平。化痰止咳。主咳喘痰多。
岩白菜:为虎耳科岩白菜属植物岩白菜以根状茎或全草入药。甘、微涩,凉。入肝、脾二经。清热解毒,止血,调经。用于肺结核咳嗽,咯血,吐血,衄血,便血,肠炎,痢疾,功能性子宫出血,白带,月经不调;外用治黄水疮。
淡豆豉:辛、甘、微苦,寒,性平;归肺,胃经。解肌发表,宣郁除烦。主治外感表证,寒热头痛,心烦,胸闷,虚烦不眠。《名医别录》:“主伤寒头痛寒热,瘴气恶毒,烦躁满闷,虚劳喘吸,两脚疼冷。又杀六畜胎子诸毒。”《日华子本草》:“治中毒药,蛊气,疟疾,骨蒸;并治犬咬。”解肌发表,宣郁除烦。主治外感表证,寒热头痛,心烦,胸闷,虚烦不眠。
白扁豆:本品为豆科扁豆属植物扁豆的干燥成熟种子。甘,微温。归脾、胃经。健脾化湿,和中消暑。用于脾胃虚弱,食欲不振,大便溏泻,白带过多,暑湿吐泻,胸闷腹胀。
防风:味辛,甘,性微温;入膀胱经、肺经、脾经、肝经。功用祛风解表、胜湿止痛、解痉、止痒。用于外感风寒,头痛身痛,风湿痹痛,骨节酸痛,腹痛泄泻,肠风下血,破伤风,风疹瘙痒,疮疡初起。《日华子本草》:“治三十六般风,男子一切劳劣,补中益神,风赤眼,止泪及瘫缓,通利五脏关脉,五劳七伤,羸损盗汗,心烦体重,能安神定志,匀气脉。”《长沙药解》:“行经络,逐湿淫,通关节,止疼痛,舒筋脉,伸急孪,活肢节,起瘫痪,敛自汗、盗汗,断漏下、崩中。”功用祛风解表、胜湿止痛、解痉、止痒。
生姜:辛、甘、温。归肺、胃经。辛温解表,温胃散寒,温肺祛痰,止呕。生姜指姜属植物的块根茎,别名紫姜,生姜,鲜姜,老姜。性温,其特有的“姜辣素”能刺激胃肠黏膜,使胃肠道充血,消化能力增强,能有效地治疗吃寒凉食物过多而引起的腹胀、腹痛、腹泻、呕吐等。
玳玳花:为芸香利植物玳玳花的花蕾。辛;甘;微苦;性平。疏肝,和胃,理气。治胸中痞闷,脘腹胀痛,呕吐、少食。理气宽胸;和胃止呕。主胸中痞闷;脘腹胀痛;不思饮食;恶心呕吐。
以下采用实施例来详细说明本发明的实施方式,借此对本发明如何应用技术手段来解决技术问题,并达成技术效果的实现过程能充分理解并据以实施。
实施例1 本发明的喷雾剂
取沙参24g、梨皮19g、天花粉7g、葛根22g、贝母23g、玉竹22g、竹根七10g、石耳15g、芦竹根18g、杉叶藻15g、猪獠参11g、生黄芪31g、党参19g、凤凰衣10g、鸡肫草15g、甘草17g、霜桑叶9g、桔梗20g、骆驼蓬13g、光头前胡12g、六月寒6g、水珠草13g、生地黄36g、粳米15g、无爷藤13g、柠条9g、蜂窝草12g、樱草根11g、岩白菜18g、淡豆豉18g、白扁豆21g、防风15g、生姜12g和玳玳花16g。
其制备方法包括以下步骤:
a、按所述比例称取所有原料药材,加相对于获得的混合物质量3倍的水浸泡10小时,武火煮沸后,改用文火慢煎30分钟至药液的剂量为300ml,煎煮3次,合并煎煮液过滤,滤液加热得浸膏1,药渣备用;
b、将步骤a的药渣加60%乙醇浸泡1.5小时,提取两次,每次1小时,合并提取液, 160目滤过, 10000转/分钟离心后的上清液,经截流分子量为10000的超滤柱超滤,超滤液减压浓缩得相对密度为80℃时1.35的浸膏2;
c、将浸膏1和浸膏2混合,加水稀释即得喷雾剂。
实施例2 本发明的含片剂
取沙参27g、梨皮17g、天花粉6g、葛根28g、贝母18g、玉竹25g、竹根七12g、石耳13g、芦竹根15g、杉叶藻16g、猪獠参13g、生黄芪35g、党参27g、凤凰衣9g、鸡肫草13g、甘草16g、霜桑叶11g、桔梗15g、骆驼蓬14g、光头前胡11g、六月寒10g、水珠草14g、生地黄29g、粳米11g、无爷藤11g、柠条11g、蜂窝草13g、樱草根14g、岩白菜15g、淡豆豉16g、白扁豆17g、防风13g、生姜17g和玳玳花15g。
其制备方法包括以下步骤:
第一步,将沙参、梨皮、天花粉、葛根、贝母、玉竹和竹根七所述比例混合,用相对于获得的混合物质量的6倍的醇浓度95%的乙醇浸泡,加热回流2小时后提取,过滤;将滤渣再次用相对于获得的混合物质量的3倍的醇浓度95%的乙醇浸泡,加热回流1小时后提取,过滤;合并两次过滤液,减压回收乙醇并浓缩至药液浓度为1.2g生药/mL,利用体积为5L的大孔吸附树脂柱洗脱两次,先用5倍树脂柱体积的去离子水或蒸馏水洗脱,再用3倍树脂柱体积的醇浓度为95%乙醇洗脱,收集乙醇洗脱液,减压浓缩除去乙醇,干燥并粉碎成粉末;
第二步,将芦竹根、杉叶藻、猪獠参、生黄芪和党参按所述比例混合,加相对于获得的混合物质量的3倍的醇浓度95%的乙醇加热回流提取2次,两次提取液合并,用管式离心机离心除杂,将除杂后的提取液于70℃的条件下减压浓缩至60℃时相对密度为1.23的膏体,将浓缩后的膏体用喷雾干燥器干燥成粉末;
第三步,将剩余原料药材按所述比例混合,加相对于获得的混合物质量的4倍的水浸泡,加热煎煮2小时,过滤;将滤渣再次用相对于获得的混合物质量的3倍的水浸泡,加热煎煮2小时,过滤;合并两次过滤液,减压浓缩除去水分,干燥并粉碎成粉末;
第四步,将第一步、第二步和第三步获得的粉末混合,进一步加入相对于获得的混合物质量0.1倍的羧甲基淀粉钠、0.1倍的微晶纤维素,混匀,制粒,干燥后,加入相对于获得的混合物质量0.05倍的硬脂酸镁,然后用冲压装置将颗粒压制成片,即得含片剂。
实施例3 本发明的颗粒剂
取沙参30g、梨皮15g、天花粉8g、葛根26g、贝母21g、玉竹19g、竹根七14g、石耳11g、芦竹根19g、杉叶藻13g、猪獠参14g、生黄芪27g、党参22g、凤凰衣7g、鸡肫草14g、甘草11g、霜桑叶15g、桔梗18g、骆驼蓬15g、光头前胡8g、六月寒8g、水珠草15g、生地黄33g、粳米10g、无爷藤17g、柠条7g、蜂窝草11g、樱草根12g、岩白菜19g、淡豆豉14g、白扁豆23g、防风12g、生姜16g和玳玳花14g。
其制备方法包括以下步骤:
步骤一:将所述原料药材按所述比例混合,加相对于混合物7倍的醇浓度为95%的乙醇,加热至沸腾回流5小时,过滤,采用渗漉法以每分钟2ml的速度缓缓渗漉,收集渗漉液,随后在真空度0.09Mpa下减压浓缩至60℃时相对密度为1.10的膏体,喷雾干燥,喷雾干燥机的进风温度175℃、出风温度85℃,随后粉碎成粉末,制成干膏粉;
步骤二:在获得的干膏粉中加入相对于干膏粉质量0.4倍的蔗糖粉和0.2倍的糊精,制成颗粒,于50℃干燥,获得颗粒剂。
毒性实验:
急性毒性试验:应用NIH小鼠40只,SPF级,雌雄各半,体重17~24g,进行急性毒性试验。小鼠随机分为两组,每组20只,即对照组和给药组,实验前禁食12小时;将本发明的实施例3制备的颗粒剂溶解在水中,(浓度为5.74g生药/ml,最高浓度)灌胃,灌胃容积为5ml/kg(即单次给药剂量为28.7生药/kg),对照组给予等量生理盐水,一天给药2次,给药间隔时间6小时,给药后连续观察14天,并记录小鼠的的毒性反应及死亡数。实验结果表明:与对照组比较,给药后小鼠未见明显差异,实验连续观察14天,小鼠全身状况、饮食、饮水、体重增长均正常。小鼠口服灌胃本发明的颗粒剂LD50>28.7生药/kg,每日最大给药量为57.4生药/kg/日。本发明的中药临床用药量为4.6g生药/日/人,成人体重以60KG计,平均用药剂量为0.077g生药/kg/日。按体重计:小鼠(平均体重以21g计)口服灌胃本发明的中药的耐受量为临床用量的745倍。因此本发明实施例3的颗粒剂急性毒性低,临床用药安全。
长期毒性实验:将本发明实施例1的喷雾剂对小鼠按6.43、15.72和36.41g生药/kg连续用药16周(1.0ml/100g体重,每天2次)及停药4周后,结果表明:本发明中药制剂对小鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药16周及停药4周后,小鼠各脏器均无明显改变。说明本发明中药制剂对小鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
长期毒性实验:将本发明实施例2的含片剂对小鼠按6.43、15.72和36.41g生药/kg连续用药16周(1.0ml/100g体重,每天2次)及停药4周后,结果表明:本发明中药制剂对小鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药16周及停药4周后,小鼠各脏器均无明显改变。说明本发明中药制剂对小鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
临床资料:
病例选择:选自确诊的燥邪伤肺型肺炎链球菌感染性肺炎患者共256例, 其中男性168 例, 女性88例,年龄最小18岁,最大56岁。所有患者均经我院胸部X线、血常规、痰涂片等检查后确诊为肺炎链球菌感染性肺炎,中医辨证为燥邪伤肺型。随机分为四组,四组差异无统计学意义(P>0.05),具有可比性。
喷雾剂治疗组:64人,男42人,女22人。
含片剂治疗组:64人,男42人,女22人。
颗粒剂治疗组:64人,男42人,女22人。
西药对照组:64人,男42人,女22人。
诊断标准:
1、病史及症状:有受凉史,起病急骤,高热、寒战,全身肌肉酸痛。咳嗽痰呈铁锈色。可伴有胸痛。
2、体征:体温升高,患处肺部叩诊呈浊音,触觉语颤增强并可闻及支气管呼吸音和湿罗音。
3、辅助检查:①胸部X线检查:早起见肺纹理增粗或受累的肺段、肺叶稍模糊;典型改变为大片炎性侵润影或实变影,以肺段或非也分布。②血常规白血细胞比值增高。③痰细菌培养有肺炎链球菌生长。
中医诊断标准:
燥邪伤肺型,证见唇、舌、鼻均干,干咳少痰,痰粘难以咯出,咽喉干痛,口渴,舌红,脉数。
凡符合上述临床诊断标准确诊为肺炎链球菌感染性肺炎,中医辨证符合燥邪伤肺型。
治疗方法:
喷雾剂治疗组:使用本发明实施例1制备的喷雾剂,每日3次,每次喷3下,5天为1个疗程。
含片剂治疗组:服用本发明实施例2制备的含片剂,每日3次,每次4片,5天为1个疗程。
颗粒剂治疗组:服用本发明实施例3制备的颗粒剂,每日3次,每次1包,5天为1个疗程。
西药对照组:青霉素80万单位, 肌注,1日2次或1200 万单位, 静滴; 链霉素0.5g 肌注, 1日2 次;5天为1个疗程。若应用上述抗生素3日, 体温不下降, 症状、体征无改善, 改用其他抗生素, 如先锋霉素Ⅳ、氨苄青霉素、红霉素或选用敏感抗生素,常规用量。
疗效评定标准:
痊愈: 临床症状、体征消失,体温降至正常,血白细胞总数及中性粒细胞降至正常,X线肺片检查病灶吸收;
显效: 临床症状、体征消失或大部分消失(2/3以上),血白细胞总数及中性粒细胞降至正常,X线检查病灶大部分(2/3以上)吸收;
有效: 临床症状、体征部分消失(1/2以上),血白细胞总数及中性粒细胞降至正常或接近正常,X线检查病灶部分吸收(1/2以上);
无效: 临床症状、体征、血白细胞总数及中性粒细胞、X线检查均无明显改善或加重。
治疗结果:
参见表1和表2,从表1可以看出,采用本发明的药物治疗燥邪伤肺型肺炎链球菌感染性肺炎,相对于西药在治疗效果上,具有显著的改进;从表2可以看出,采用本发明的药物治疗燥邪伤肺型肺炎链球菌感染性肺炎,相对于西药,在治疗疗程上显著缩短。
表1 四组分别治疗10天后临床疗效比较 例
组别 | 例数 | 痊愈 | 显效 | 有效 | 无效 | 总有效率 |
喷雾剂治疗组 | 64 | 42 | 16 | 6 | 0 | 100% |
含片剂治疗组 | 64 | 45 | 15 | 3 | 1 | 98.4% |
颗粒剂治疗组 | 64 | 41 | 19 | 4 | 0 | 100% |
西药对照组 | 64 | 28 | 17 | 7 | 12 | 81.3% |
表2 四组分别治疗10天后痊愈和显效的人数和时间比较 例(%)
组别 | 例数 | 第1-5天 | 第6-10天 |
喷雾剂治疗组 | 58 | 35(60.3%) | 23(39.7%) |
含片剂治疗组 | 60 | 34(56.7%) | 26(43.3%) |
颗粒剂治疗组 | 60 | 38(63.3%) | 22(36.7) |
西药对照组 | 45 | 21(46.7%) | 24(53.3%) |
根据上述表格内的临床统计可知,本发明提供的药物制剂具有起效快、有效率高、疗效确切、安全性高、无毒副作用的优势。
对上述四组痊愈和显效的患者随访一年,喷雾剂治疗组、含片剂治疗组和颗粒剂治疗组均无复发。
西药对照组痊愈的28例,复发3例,显效的17例,复发5例,复发率17.8%。
典型病例:
患者吕某,男,52岁,主诉感冒后自服感冒药治疗,现体温39.9℃,左胸部痛,咳嗽3天,头痛、寒战,证见唇、舌、鼻均干,干咳少痰,痰粘难以咯出,咽喉干痛,口渴,舌红,脉数。胸体查:左肺呼吸减弱,白血球15900,中性粒细胞在80%以上,细胞内可见中毒颗粒。X线透视:左肺野中部内侧大片炎性侵润影;痰直接涂片作革兰氏染色及荚膜染色镜检,发现典型的革兰氏染色阳性、带荚膜的双球菌或链球菌。诊断:为肺炎链球菌感染性肺炎,中医辨证燥邪伤肺型。使用本发明药物制剂实施例3的颗粒剂,每日3次,每次1包,3天后,咳嗽症状明显减轻,5天后基本消失。但剧烈活动后仍有明显咳嗽,继续使用2天痊愈。嘱其防寒保暖,随访一年未复发。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种治疗肺炎链球菌感染性肺炎的药物,其特征在于,包括以下原料药材:沙参、梨皮、天花粉、葛根、贝母、玉竹、竹根七、石耳、芦竹根、杉叶藻、猪獠参、生黄芪、党参、凤凰衣、鸡肫草、甘草、霜桑叶、桔梗、骆驼蓬、光头前胡、六月寒、水珠草、生地黄、粳米、无爷藤、柠条、蜂窝草、樱草根、岩白菜、淡豆豉、白扁豆、防风、生姜和玳玳花。
2.根据权利要求1所述的药物,其特征在于,所述药物中各原料药材的重量份数比为:沙参22-32份、梨皮12-21份、天花粉5-9份、葛根20-30份、贝母16-25份、玉竹17-27份、竹根七9-15份、石耳10-16份、芦竹根13-20份、杉叶藻12-17份、猪獠参10-15份、生黄芪26-39份、党参16-29份、凤凰衣6-11份、鸡肫草12-16份、甘草10-18份、霜桑叶8-16份、桔梗14-21份、骆驼蓬12-16份、光头前胡7-14份、六月寒5-11份、水珠草12-17份、生地黄28-38份、粳米9-17份、无爷藤10-19份、柠条6-12份、蜂窝草8-14份、樱草根10-15份、岩白菜14-20份、淡豆豉13-19份、白扁豆15-25份、防风11-16份、生姜11-19份和玳玳花13-19份。
3.根据权利要求1或2所述的药物,其特征在于,所述药物中各原料药材的重量份数比为:沙参24-30份、梨皮15-19份、天花粉6-8份、葛根22-28份、贝母18-23份、玉竹19-25份、竹根七10-14份、石耳11-15份、芦竹根15-19份、杉叶藻13-16份、猪獠参11-14份、生黄芪27-35份、党参19-27份、凤凰衣7-10份、鸡肫草13-15份、甘草11-17份、霜桑叶9-15份、桔梗15-20份、骆驼蓬13-15份、光头前胡8-12份、六月寒6-10份、水珠草13-15份、生地黄29-36份、粳米10-15份、无爷藤11-17份、柠条7-11份、蜂窝草9-13份、樱草根11-14份、岩白菜15-19份、淡豆豉14-18份、白扁豆17-23份、防风12-15份、生姜12-17份和玳玳花14-16份。
4.根据权利要求1-3任一所述的药物,其特征在于,所述药物中各原料药材的重量份数比为:沙参24份、梨皮19份、天花粉7份、葛根22份、贝母23份、玉竹22份、竹根七10份、石耳15份、芦竹根18份、杉叶藻15份、猪獠参11份、生黄芪31份、党参19份、凤凰衣10份、鸡肫草15份、甘草17份、霜桑叶9份、桔梗20份、骆驼蓬13份、光头前胡12份、六月寒6份、水珠草13份、生地黄36份、粳米15份、无爷藤13份、柠条9份、蜂窝草12份、樱草根11份、岩白菜18份、淡豆豉18份、白扁豆21份、防风15份、生姜12份和玳玳花16份。
5.根据权利要求1-3任一所述的药物,其特征在于,所述药物中各原料药材的重量份数比为:沙参27份、梨皮17份、天花粉6份、葛根28份、贝母18份、玉竹25份、竹根七12份、石耳13份、芦竹根15份、杉叶藻16份、猪獠参13份、生黄芪35份、党参27份、凤凰衣9份、鸡肫草13份、甘草16份、霜桑叶11份、桔梗15份、骆驼蓬14份、光头前胡11份、六月寒10份、水珠草14份、生地黄29份、粳米11份、无爷藤11份、柠条11份、蜂窝草13份、樱草根14份、岩白菜15份、淡豆豉16份、白扁豆17份、防风13份、生姜17份和玳玳花15份。
6.根据权利要求1-3任一所述的药物,其特征在于,所述药物中各原料药材的重量份数比为:沙参30份、梨皮15份、天花粉8份、葛根26份、贝母21份、玉竹19份、竹根七14份、石耳11份、芦竹根19份、杉叶藻13份、猪獠参14份、生黄芪27份、党参22份、凤凰衣7份、鸡肫草14份、甘草11份、霜桑叶15份、桔梗18份、骆驼蓬15份、光头前胡8份、六月寒8份、水珠草15份、生地黄33份、粳米10份、无爷藤17份、柠条7份、蜂窝草11份、樱草根12份、岩白菜19份、淡豆豉14份、白扁豆23份、防风12份、生姜16份和玳玳花14份。
7.根据权利要求1-6任一所述的药物,其特征在于,所述药物的剂型为喷雾剂时,其制备方法包括以下步骤:
a、按所述比例称取所有原料药材,加相对于获得的混合物质量3-5倍的水浸泡3-10小时,武火煮沸后,改用文火慢煎30-50分钟至药液的剂量为100-300ml,煎煮3次,合并煎煮液过滤,滤液加热得浸膏1,药渣备用;
b、将步骤a的药渣加60-90%乙醇浸泡0.5-1.5小时,提取两次,每次1-2小时,合并提取液,80-160目滤过,取6000-10000转/分钟离心后的上清液,经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩得相对密度为80℃时 1.35的浸膏2;
c、将浸膏1和浸膏2混合,加水稀释即得喷雾剂。
8.根据权利要求1-6任一所述的药物,其特征在于,所述药物的剂型为含片剂时,其制备方法包括以下步骤:
第一步,将沙参、梨皮、天花粉、葛根、贝母、玉竹和竹根七所述比例混合,用相对于获得的混合物质量的4~6倍的醇浓度90%~95%的乙醇浸泡,加热回流2~4小时后提取,过滤;将滤渣再次用相对于获得的混合物质量的2~4倍的醇浓度85%~95%的乙醇浸泡,加热回流1~2小时后提取,过滤;合并两次过滤液,减压回收乙醇并浓缩至药液浓度为0.8~1.2g生药/mL,利用体积为5L的大孔吸附树脂柱洗脱两次,先用5倍树脂柱体积的去离子水或蒸馏水洗脱,再用3倍树脂柱体积的醇浓度为90%~95%乙醇洗脱,收集乙醇洗脱液,减压浓缩除去乙醇,干燥并粉碎成粉末;
第二步,将芦竹根、杉叶藻、猪獠参、生黄芪和党参按所述比例混合,加相对于获得的混合物质量的3~5倍的醇浓度85%~95%的乙醇加热回流提取2次,两次提取液合并,用管式离心机离心除杂,将除杂后的提取液于60℃~70℃的条件下减压浓缩至60℃时相对密度为1.20~1.23的膏体,将浓缩后的膏体用喷雾干燥器干燥成粉末;
第三步,将剩余原料药材按所述比例混合,加相对于获得的混合物质量的2~5倍的水浸泡,加热煎煮2~4小时,过滤;将滤渣再次用相对于获得的混合物质量的1~3倍的水浸泡,加热煎煮1~2小时,过滤;合并两次过滤液,减压浓缩除去水分,干燥并粉碎成粉末;
第四步,将第一步、第二步和第三步获得的粉末混合,进一步加入相对于获得的混合物质量0.05~0.1倍的羧甲基淀粉钠、0.05~0.1倍的微晶纤维素,混匀,制粒,干燥后,加入相对于获得的混合物质量0.01~0.05倍的硬脂酸镁,然后用冲压装置将颗粒压制成片,即得含片剂。
9.根据权利要求1-6任一所述的药物,其特征在于,所述药物的剂型为颗粒剂时,其制备方法包括以下步骤:
步骤一:将所述原料药材按所述比例混合,加相对于混合物4~8倍的醇浓度为85%~95%的乙醇,加热至沸腾回流3~5小时,过滤,采用渗漉法以每分钟1~2ml的速度缓缓渗漉,收集渗漉液,随后在真空度0.06~0.09Mpa下减压浓缩至50~60℃时相对密度为1.04~1.10的膏体,喷雾干燥,喷雾干燥机的进风温度160~175℃、出风温度80~85℃,随后粉碎成粉末,制成干膏粉;
步骤二:在获得的干膏粉中加入相对于干膏粉质量0.2~0.4倍的蔗糖粉和0.1~0.2倍的糊精,制成颗粒,于40~50℃干燥,获得颗粒剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510167902.9A CN104707126A (zh) | 2015-04-10 | 2015-04-10 | 一种治疗肺炎链球菌感染性肺炎的药物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510167902.9A CN104707126A (zh) | 2015-04-10 | 2015-04-10 | 一种治疗肺炎链球菌感染性肺炎的药物及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104707126A true CN104707126A (zh) | 2015-06-17 |
Family
ID=53407170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510167902.9A Withdrawn CN104707126A (zh) | 2015-04-10 | 2015-04-10 | 一种治疗肺炎链球菌感染性肺炎的药物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104707126A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107373253A (zh) * | 2017-08-07 | 2017-11-24 | 南京正宽医药科技有限公司 | 一种润肺饮料及制备方法和应用 |
CN115475209A (zh) * | 2022-10-09 | 2022-12-16 | 李庭玉 | 一种药物组合物及其制剂和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103251864A (zh) * | 2013-05-28 | 2013-08-21 | 高志芳 | 一种治疗肺炎的中药及其制备方法 |
-
2015
- 2015-04-10 CN CN201510167902.9A patent/CN104707126A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103251864A (zh) * | 2013-05-28 | 2013-08-21 | 高志芳 | 一种治疗肺炎的中药及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107373253A (zh) * | 2017-08-07 | 2017-11-24 | 南京正宽医药科技有限公司 | 一种润肺饮料及制备方法和应用 |
CN115475209A (zh) * | 2022-10-09 | 2022-12-16 | 李庭玉 | 一种药物组合物及其制剂和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102784363B (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN103736072A (zh) | 一种治疗过敏性鼻炎的药物及其制备方法 | |
CN103041256B (zh) | 一种治疗小儿反复呼吸道感染的中药制剂 | |
CN103520655A (zh) | 一种治疗寻常型银屑病的中药组合物及其制备方法 | |
CN103041257B (zh) | 治疗小儿发热高烧呼吸道感染的中药制剂 | |
CN104398938A (zh) | 一种治疗风热犯肺型大叶性肺炎的中药及制备方法 | |
CN103495072B (zh) | 一种治疗支气管扩张病的中药组合物及其制备方法 | |
CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
CN103041255B (zh) | 治疗小儿咽喉肿痛呼吸道感染的中药制剂 | |
CN104707126A (zh) | 一种治疗肺炎链球菌感染性肺炎的药物及制备方法 | |
CN105055984A (zh) | 一种治疗哮喘的中药组合物及其制备方法 | |
CN104998197A (zh) | 一种用于治疗肝癌的中药组合物 | |
CN105435197A (zh) | 一种治疗桥本氏病的药物组合物及其制备方法 | |
CN104056242A (zh) | 一种治疗急性胆囊炎的中药组合物及其制备方法 | |
CN106267028A (zh) | 一种治疗肺炎的中药组合物及其制备方法 | |
CN103860942A (zh) | 用于治疗痰浊结聚型鼻咽癌的药物及其制备方法 | |
CN104666475A (zh) | 一种治疗干燥综合症的黄连阿胶组合物及其应用 | |
CN105561267A (zh) | 一种中药组合物在制备治疗急性胆囊炎的药物中的应用 | |
CN103735906A (zh) | 一种治疗干性支气管扩张的中药制剂及其制备方法 | |
CN103041258B (zh) | 治疗小儿呼吸道感染伴纳差不食的中药制剂 | |
CN104740162A (zh) | 一种治疗肺炎链球菌性肺炎痰热壅肺证的药物与及其制备方法 | |
CN106511812A (zh) | 一种治疗伤风感冒的药物及其制备方法 | |
CN105596497A (zh) | 一种治疗胰腺炎的药物组合物 | |
CN105267815A (zh) | 一种治疗小儿肺肾两虚型哮喘的喷雾剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20150617 |